Small molecule · Cytotoxic · developed by Imunon
Lyso-Thermosensitive Liposome Doxorubicin (ThermoDox) is a temperature-sensitive liposomal formulation of the anthracycline doxorubicin. When activated by external heat (40-41°C), the liposomes release doxorubicin at the tumor site while sparing normal tissues. It is studied in breast cancer, lung cancer, hepatocellular carcinoma, and bone metastases.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT02112656 | Phase 3 | Hepatocellular Carcinoma | Completed | IMNN |
| NCT02850419 | Phase 2 | Breast Cancer | Withdrawn | IMNN |
| NCT01640847 | Phase 2 | Painful Bone Metastases | Withdrawn | IMNN |
| NCT02181075 | Phase 1 | Liver Tumour | Completed | IMNN |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
AdenocarcinomaBreast CancerBreast CarcinomaHepatocellular CarcinomaLiver TumourNon-small Cell Lung CancerPainful Bone MetastasesSmall Cell Lung Cancer
Updated Oct 3, 2026. Something wrong or missing? Report it on the IMNN page.
See IMNN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
IMNN catalysts and pipeline →